UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   Form 10-QSB

(Mark One)
        [X]    QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE
               SECURITIES EXCHANGE ACT OF 1934

               For the quarterly period ended:           April 30, 2002
                                              ----------------------------------

        [  ]   TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE
               EXCHANGE ACT

               For the transition period from                to
                                              --------------    ----------------

                      Commission file number                002-91824-D
                                            ------------------------------------

                            My Meds Express.Com, Inc.
                            -------------------------
        (Exact name of small business issuer as specified in its charter)

               Delaware                                   84-1398190
               ---------                                  -----------
        (state or other jurisdiction of        (IRS Employer Identification No.)
        incorporation or organization)

                        BOX 8029, La Jolla, CA 92037-8029
                    (Address of principal executive offices)

                                 (619) 456-7176
                            Issuer's telephone number


APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practical date: April 30, 2002 2,177,647

Transitional Small Business Disclosure Format (check one). Yes      ;  No   X
                                                               ----         -





<PAGE>



                         PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements


                          INDEPENDENT AUDITOR'S REPORT


My Meds Express.Com, Inc.
(A Development Stage Company)

        We have reviewed the accompanying balance sheets of My Meds Express.Com,
Inc. (a  development  stage company) as of April 30, 2002 and July 31, 2001, and
the  related  statements  of  operations  for the three and nine months and cash
flows for the nine  months  ended  April  30,  2002 and  2001.  These  financial
statements are the responsibility of the Company's management.

        We conducted our review in accordance with standards  established by the
American  Institute  of  Certified  Public  Accountants.  A  review  of  interim
financial  information consists principally of applying analytical procedures to
financial  data and making  inquiries of persons  responsible  for financial and
accounting matters. It is substantially less in scope than an audit conducted in
accordance with generally accepted auditing standards, the objective of which is
the expression of an opinion regarding the financial statement taken as a whole.
Accordingly, we do not express such an opinion.

        Based on our review, we are not aware of any material modifications that
should  be made  to the  accompanying  financial  statements  for  them to be in
conformity with generally accepted accounting principles.

                                                   Respectfully submitted



                                                   /S/ ROBISON, HILL & CO.
                                                   Certified Public Accountants
Salt Lake City, Utah
June 6, 2002













<PAGE>



                            MY MEDS EXPRESS.COM, INC.
                          (A Development Stage Company)
                                 BALANCE SHEETS
                                   (Unaudited)
<TABLE>
<CAPTION>

                                                                  April 30,        July 31,
                                                                    2002             2001
                                                               ---------------  --------------

<S>                                                            <C>              <C>
Assets:                                                        $             -  $            -
                                                               ===============  ==============

Liabilities - Accounts Payable                                 $         1,931  $        4,006
Shareholder Advances                                                    12,889           8,105
                                                               ---------------  --------------

     Total Liabilities                                                  14,820          12,111
                                                               ---------------  --------------

Stockholders' Equity:
  Convertible Preferred Stock,
    Par value $.001,
    Authorized 5,000,000,
    Issued 630 shares issued at April 30, 2002
     and July 31, 2001                                                       1               1
  Common Stock Authorized
    Par value $.001,
    Authorized 50,000,000,
    Issued 2,177,647 shares issued at April 30, 2002
    and at July 31, 2001                                                 2,178           2,178
  Paid-In Capital                                                    2,934,636       2,934,636
  Retained Deficit                                                  (2,933,986)     (2,933,986)
  Deficit Accumulated During the
    Development Stage                                                  (17,649)        (14,940)
                                                               ---------------  --------------

     Total Stockholders' Equity                                        (14,820)        (12,111)
                                                               ---------------  --------------

     Total Liabilities and
       Stockholders' Equity                                    $             -  $            -
                                                               ===============  ==============
</TABLE>







                 See accompanying notes and accountants' report



<PAGE>




                            MY MEDS EXPRESS.COM, INC.
                          (A Development Stage Company)
                             STATEMENT OF OPERATIONS
                                   (Unaudited)
<TABLE>
<CAPTION>


                                                                                  Cumulative
                                                                                    Since
                                                                                April 2, 1996
                    For the Three Months Ended     For the Nine Months Ended     Inception of
                            April 30,                      April 30,             Development
                        2002           2001           2002           2001           Stage
                  --------------- -------------- -------------- --------------- --------------
<S>               <C>             <C>            <C>            <C>             <C>
Revenues          $             - $            - $            - $             - $            -
                  --------------- -------------- -------------- --------------- --------------

Expenses                      836            622          2,709           3,322         17,649
                  --------------- -------------- -------------- --------------- --------------

       Net Loss   $          (836)$         (622)$       (2,709)$        (3,322)$      (17,649)
                  =============== ============== ============== =============== ==============



Basic & Diluted
  Loss per Share  $             - $            - $            - $             -
                  =============== ============== ============== ===============
</TABLE>






















                 See accompanying notes and accountants' report


<PAGE>



                            MY MEDS EXPRESS.COM, INC.
                          (A Development Stage Company)
                             STATEMENT OF CASH FLOWS
                                   (Unaudited)
<TABLE>
<CAPTION>
                                                                                  Cumulative
                                                                                    Since
                                                                                April 2, 1996
                                                                                  Inception
                                                  For the Nine Months Ended           of
                                                          April 30,              Development
                                               -------------------------------
                                                    2002            2001            Stage
                                               --------------- ---------------  --------------
CASH FLOWS FROM OPERATING
ACTIVITIES:
<S>                                            <C>             <C>              <C>
Net Loss                                       $        (2,709)$        (3,322) $      (17,649)
Increase (Decrease) in Accounts Payable                 (2,075)          3,322             465
                                               --------------- ---------------  --------------
  Net Cash Used in operating activities                 (4,784)              -         (17,184)
                                               --------------- ---------------  --------------

CASH FLOWS FROM INVESTING
ACTIVITIES:
  Net cash provided by investing activities                  -               -               -
                                               --------------- ---------------  --------------

CASH FLOWS FROM FINANCING
ACTIVITIES:
Proceeds From Shareholder Advances                       4,784               -          12,889
Proceeds From Capital Stock Issued                           -               -           4,295
                                               --------------- ---------------  --------------
  Net cash provided by financing activities              4,784               -          17,184
                                               --------------- ---------------  --------------

Net (Decrease) Increase in
  Cash and Cash Equivalents                                  -               -               -
Cash and Cash Equivalents
  at Beginning of Period                                     -               -               -
                                               --------------- ---------------  --------------
Cash and Cash Equivalents
  at End of Period                             $             - $             -  $            -
                                               =============== ===============  ==============

SUPPLEMENTAL DISCLOSURE
-----------------------
OF CASH FLOW INFORMATION:
-------------------------
Cash paid during the year for:
  Interest                                     $             - $             -  $            -
  Franchise and income taxes                   $             - $             -  $        1,646
</TABLE>
SUPPLEMENTAL DISCLOSURE OF NON-
CASH INVESTING AND FINANCING
ACTIVITIES:
  None

                 See accompanying notes and accountants' report


<PAGE>


                            MY MEDS EXPRESS.COM, INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                    FOR THE NINE MONTHS ENDED APRIL 30, 2002
                                   (Unaudited)

NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

        The accompanying  unaudited  financial  statements have been prepared in
accordance with generally  accepted  accounting  principles and with Form 10-QSB
requirements.  Accordingly,  they  do not  include  all of the  information  and
footnotes  required by generally  accepted  accounting  principles  for complete
financial statements.  In the opinion of management,  all adjustments considered
necessary for a fair presentation have been included.  Operating results for the
nine month period ended April 30, 2002,  are not  necessarily  indicative of the
results that may be expected for the year ended July 31, 2002.

Organization and Basis of Presentation

        Plaza  Group,  Inc.,  hereinafter  referred  to  as  the  "Company"  was
incorporated  on April 24, 1984 under the laws of the State of Delaware  for the
principal purpose of engaging in any and all types of business properties.

General

        On November 7, 1984 the United States Securities and Exchange Commission
granted  an  effective  date to a  registration  statement  on S-18 filed by the
Company  in  the  Denver  office,  as  Commission  File  Number  2-91824-D.  The
registration statement was for offering of 800,000 Units at $0.50 per unit.

        The offering file by the Company was a "Blank  Check"offering  and since
the date of incorporation the company has not engaged in any meaningful business
and is considered a development stage company.  The company ceased all operating
activities  during  the  period  from July 31,  1987 to March  24,  1996 and was
considered dormant.

        The  proposed  business  activities  described  herein may  classify the
Company as a "Blank Check" company. Many states have entered statutes, rules and
regulations  limiting the sale of securities of "Blank Check" companies in their
respective  jurisdictions.  In order to comply with these  various  limitations,
management  does not intend to  undertake  any  efforts  to sell any  additional
securities of the Company,  either debt or equity,  or cause a market to develop
in the  Company's  securities  until such time as the Company  has  successfully
implemented its business plan described herein.

        On April 2, 1996, the Company obtained a certificate of renewal from the
State of  Delaware.  On April 2, 1996 the  Company  obtained  a  certificate  of
amendment of "Plaza Group, Inc., changing




<PAGE>



                            MY MEDS EXPRESS.COM, INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                    FOR THE NINE MONTHS ENDED APRIL 30, 2002
                                   (Unaudited)

NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(Continued)

General (Continued)

the name from Plaza  Group,  Inc to Union 69,  Ltd. On March 2, 2000 the Company
changed its name to Save on Meds.Com, Inc.

Nature of Business

        The Company's purpose is to seek, investigate and, if such investigation
warrants,  acquire an  interest  in business  opportunities  presented  to it by
persons  or firms who or which  desire  to seek the  perceived  advantages  of a
Corporation which reports under Section 13 and 15 of the Securities Exchange Act
of 1934 ( the "Exchange  Act").  The Company will not restrict its search to any
specific  business;  industry  or  geographical  location  and the  Company  may
participate in a business  venture of virtually  unlimited  discretion to search
for and enter into potential business opportunities. Management anticipates that
it may be able to participate on only one potential business venture because the
Company  has  nominal  assets  and  limited  financial  resources.  This lack of
diversification  should be considered a substantial  risk ro shareholders of the
Company because it will not permit the Company to offset  potential  losses from
one venture against gains from another.

Cash and Cash Equivalents

        For purposes of the statement of cash flows,  the Company  considers all
highly liquid debt instruments purchased with a maturity of three months or less
to be cash equivalents to the extent the funds are not being held for investment
purposes.

Pervasiveness of Estimates

        The  preparation  of financial  statements in conformity  with generally
accepted  accounting  principles  required  management  to  make  estimates  and
assumptions  that  affect the  reported  amounts of assets and  liabilities  and
disclosure of  contingent  assets and  liabilities  at the date of the financial
statements  and the  reported  amounts  of  revenues  and  expenses  during  the
reporting period. Actual results could differ from those estimates.

Concentration of Credit Risk

        The  Company  has no  significant  off-balance-sheet  concentrations  of
credit  risk such as foreign  exchange  contracts,  options  contracts  or other
foreign hedging arrangements.



<PAGE>





                            MY MEDS EXPRESS.COM, INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                    FOR THE NINE MONTHS ENDED APRIL 30, 2002
                                   (Unaudited)

NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(Continued)

Loss Per Share:

        The reconciliations of the numerators and denominators of the basic loss
per share computations are as follows:
<TABLE>
<CAPTION>
                                                                                  Per-Share
                                                  Income           Shares           Amount
                                                  ------           ------           ------
                                                (Numerator)     (Denominator)

                                                 For the Three Months Ended April 30, 2002
Basic Loss Share
<S>                                           <C>                    <C>        <C>
Income to common shareholders                 $          (836)       2,177,647  $            -
                                              ===============  ===============  ==============

                                                  For the Nine Months Ended April 30, 2002
Basic Loss Share
Income to common shareholders                 $        (2,709)       2,177,647  $            -
                                              ===============  ===============  ==============

                                                 For the Three Months Ended April 30, 2001
Basic Loss per Share
Income to common shareholders                 $          (622)       2,177,647  $            -
                                              ===============  ===============  ==============

                                                  For the Nine Months Ended April 30, 2001
Basic Loss per Share
Loss to common shareholders                   $        (3,322)       2,177,647  $            -
                                              ===============  ===============  ==============
</TABLE>
        The  effect  of   outstanding   common   stock   equivalents   would  be
anti-dilutive or immaterial for 2002 and 2001 and are thus not considered.

NOTE 2 - CONVERTIBLE PREFERRED STOCK

        The convertible  preferred stock is convertible into common stock at the
option  of the  shareholder  at  any  time  after  issuance  of the  convertible
preferred  shares.  The conversion  ratio is one share of convertible  preferred
stock for 30,000 shares of common stock.  The holders of  convertible  preferred
stock  shall be  entitled  to vote on all  matters  at the ratio of one vote per
share of common  stock  that it is  convertible  into as if the  shares had been
converted.  In the event of any voluntary or involuntary  liquidations  (whether
complete or partial), dissolution, or winding up of the corporation, the holders
of the convertible preferred stock shall be entitled to be paid an amount in


<PAGE>



                            MY MEDS EXPRESS.COM, INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                    FOR THE NINE MONTHS ENDED APRIL 30, 2002
                                   (Unaudited)

NOTE 2 - CONVERTIBLE PREFERRED STOCK (Continued)

cash equal to the net book value of the  corporation on the date of liquidation,
plus all unpaid dividends,  whether or not previously declared,  accrued thereon
to the date of final distribution.

NOTE 3 - INCOME TAXES

        As of April 30, 2002, the Company had a net operating loss  carryforward
for income tax reporting purposes of approximately $2,952,000 that may be offset
against future taxable income through 2021. Current tax laws limit the amount of
loss  available to be offset  against  future  taxable income when a substantial
change in ownership  occurs.  Therefore,  the amount  available to offset future
taxable income may be limited. No tax benefit has been reported in the financial
statements,  because the Company  believes  there is a 50% or greater chance the
carry-forward will expire unused. Accordingly, the potential tax benefits of the
loss carry-forward are offset by a valuation allowance of the same amount.

NOTE 4 - DEVELOPMENT STAGE COMPANY/GOING CONCERN

        The Company has not begun  principal  operations and as is common with a
development  stage  company,  the Company has had  recurring  losses  during its
development  stage.  The  Company's  financial  statements  are  prepared  using
generally  accepted  accounting  principles  applicable to a going concern which
contemplates  the  realization  of assets and  liquidation of liabilities in the
normal course of business.  However,  the Company does not have significant cash
or other material  assets,  nor does it have an  established  source of revenues
sufficient to cover its  operating  costs and to allow it to continue as a going
concern.  In the interim,  shareholders of the Company have committed to meeting
its minimal operating expenses.

NOTE 5 - COMMITMENTS

        As of April 30, 2002 all  activities of the Company have been  conducted
by corporate  officers from either their homes or business  offices.  Currently,
there  are no  outstanding  debts  owed by the  company  for  the  use of  these
facilities and there are no commitments for future use of the facilities.








<PAGE>




Item 2.  Management's Discussion and Analysis or Plan of Operation.

General  - This  discussion  should  be read in  conjunction  with  Management's
Discussion and Analysis of Financial  Condition and Results of Operations in the
Company's annual report on Form 10-KSB for the year ended July 31, 2001.

Results of Operations -For the quarter ended April 30, 2002 compared to the same
period  in 2001  are not  necessarily  indicative  of the  results  that  may be
expected for the year ended July 31, 2002.

The  Company  has no  business  operations.  The  Company had $836 and $2,709 in
expenses for the three and nine month  periods ended April 30, 2002 and $622 and
$3,322 for the three and nine month  periods  ended April 30, 2001.  The Company
had no revenues  for the three and nine month  periods  ended April 30, 2002 and
2001. Losses on operations may occur until sufficient revenues can be achieved.

Liquidity and Capital Resources

        The Company  requires  working  capital  principally to fund its current
operations.  There are no formal commitments from banks or other lending sources
for lines of credit or similar  short-term  borrowing,  but the Company has been
able to borrow any additional working capital that has been required.  From time
to time in the past,  required  short-term  borrowing  have been obtained from a
principal shareholder or other related entities.

        In order to  complete  any  acquisition,  the Company may be required to
supplement  its  available  cash and other  liquid  assets  with  proceeds  from
borrowings,  the sale of additional securities,  including the private placement
of restricted stock and/or a public offering, or other sources.  There can be no
assurance  that  any such  required  additional  funding  will be  available  or
favorable to the Company.

        Because  management  controls  93.47% of voting  rights,  management may
actively  negotiate or otherwise consent to the purchase of any portion of their
stock as a condition to or in connection  with a proposed merger or acquisition.
Furthermore,  management  could consent or approve any particular  stock buy-out
transaction  without  shareholder  approval.  In the event  that an  appropriate
merger  candidate is located,  the Company may need to pay cash finder's fees or
other  acquisition  related  compensation  may be paid to  officers,  directors,
promoters  or their  affiliates.  Any such  finder's  fees  paid to an  officer,
director,  promoter,  or affiliate may present a conflict of interest because of
the non-arms length nature of such  transaction.  There are no such negotiations
in progress or contemplated.

        There  are no  arrangements  or  understandings  between  non-management
shareholders and management under which non-management shareholders may directly
or  indirectly  participate  in or influence  the  management  of the  Company's
affairs.





<PAGE>




                           PART II - OTHER INFORMATION


Item 1.  Legal Proceedings

    None.

Item 2.  Changes in Securities

    None.

Item 3.  Defaults Upon Senior Securities

    None.

Item 4.  Submission of Matters to a Vote of Security Holders.

    None.

Item 5.  Other Information

    None.

Item 6.  Exhibits and Reports on Form 8-K

        The  Company  did not file a report on Form 8-K during  the nine  months
ended April 30, 2002.



<PAGE>


                                   SIGNATURES



        In accordance with the  requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.



                                   MY MEDS EXPRESS.COM, INC.
                                  (Registrant)





DATE:   June 13, 2002                   By:  /s/
                                            ------------------------------------
                                            Michael Johnson, President
                                            (Principal Financial and
                                            Accounting Officer)